Dunckley Travis, Coon Keith D, Stephan Dietrich A
Neurogenomics Division, The Translational Genomics Research Institute, Phoenix, AZ 85004, USA.
Drug Discov Today. 2005 Mar 1;10(5):326-34. doi: 10.1016/S1359-6446(04)03353-7.
The identification of clinically relevant biomarkers for neurological diseases poses unique challenges. These include an historical lack of availability of relevant tissues from the site of pathology, relatively poorly matured techniques for disease diagnosis, the complexity and cellular heterogeneity of the brain, and a clear deficiency of models for functional validation of candidate biomarkers. Here, the unique challenges that neurological disorders introduce to biomarker discovery are described and how modern technological advances in genomics, proteomics and metabolomics are overcoming these obstacles and are driving the discovery of novel biomarkers to improve early diagnosis and therapeutic treatment is discussed.
识别神经疾病的临床相关生物标志物面临着独特的挑战。这些挑战包括:历史上缺乏来自病理部位的相关组织;疾病诊断技术相对不够成熟;大脑的复杂性和细胞异质性;以及用于候选生物标志物功能验证的模型明显不足。本文描述了神经疾病给生物标志物发现带来的独特挑战,并讨论了基因组学、蛋白质组学和代谢组学方面的现代技术进步如何克服这些障碍,推动新型生物标志物的发现以改善早期诊断和治疗。